Saudi Venture Capital invests in SEEDRA Ventures Fund II

Saudi Venture Capital (SVC) has announced its investment in SEEDRA Ventures Fund II, a venture capital fund managed by SEEDRA Ventures, an entity licensed by the Capital Market Authority of Saudi Arabia
While sector-agnostic, the Fund is geared towards technology and tech-enabled startups, including Artificial Intelligence (AI), FinTech, and Proptech. The Fund primarily targets early-stage, high-growth startups
Nora Alsarhan, CEO at SVC, said: “Early-stage venture capital investment is where Saudi Arabia’s founders meet their first institutional partners, and the depth of that segment shapes what follows. Our investment in SEEDRA Ventures Fund II supports a manager focused squarely on backing Saudi technology founders at that critical stage, expanding the specialized capital available to them and reinforcing the private-sector engine of Vision 2030”
“Saudi Arabia is producing some of the most ambitious founders and compelling venture opportunities in the region. SVC’s investment, alongside the strong demand that resulted in Fund II being oversubscribed, reinforces our conviction in the market and our ability to identify exceptional entrepreneurs early in their journey. Through Fund II, we will partner with founders as they scale their businesses by providing capital, expertise, and strategic access to our network, while maintaining a disciplined approach to delivering attractive long-term returns for our investors,” said Haitham Alforaih, Managing Partner of SEEDRA Ventures
SVC is an investment company established in 2018. It is a subsidiary of the SME Bank, part of the National Development Fund. SVC aims to stimulate and sustain financing for startups and SMEs from pre-Seed to pre-IPO through investment in funds and direct investment in startups and SMEs

  • Related Posts

    Mayo Clinic opens patient information office in Saudi Arabia

    July 22, 2026: Mayo Clinic is opening a representative office in Saudi Arabia to help patients, their families, health insurers, referring physicians and others interested in connecting with Mayo Clinic.…

    Continue reading
    Novo Nordisk receives European Commission approval ofWegovy®️ pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved

    First GLP-1 pill approved in the European Union for the treatment of obesity and overweight Only Wegovy®️ pill demonstrates 17%* mean weight loss1 and cardiovascular benefits Wegovy®️ 7.2 mg injection…

    Continue reading